Article

Novel TB Vaccine Fails to Protect Infants

A tuberculosis (TB) vaccine candidate was safe and immunogenic but not efficacious in infants, researchers reported.

In a randomized trial of 2,797 infants, the vaccine candidate was well-tolerated compared with a placebo injection and induced "modest" cell-mediated immune responses, according to Helen McShane, MD, of the University of Oxford, and colleagues.

Read the full story: http://bit.ly/WY81Eh

Source: Medpage Today

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Dr Carrie Kitko
Merrill H. Stewart, MD
Related Content
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Managed Care Cast
July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bob, MPH

Giuliana Grossi Anna Bob
Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bob, MPH, executive director of the Path Forward coalition.
Site Logo
July 2nd 2025

Guideline-Based Strategies for the Management of Cardiovascular-Renal-Metabolic Conditions: Focus on Chronic Kidney Disease

Managed Care Cast
June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD
Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.
Hidradenitis suppurativa. | Image Credit: syahrir - stock.adobe.com
July 2nd 2025

Approved Hidradenitis Suppurativa Treatments and Pipeline Show Similar Efficacy, Safety Without Head-to-Head Trials

Cameron Santoro
Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable efficacy and safety, offering hope for patients often dissatisfied with current treatment options.
In the overall population, 17.8% patients were referred to outpatient treatment. Black patients were significantly less likely to receive outpatient treatment referrals compared with White patients. | Image Credit: Stanislau_V - stock.adobe.com
July 2nd 2025

Racial Disparities in Opioid Use Disorder Treatment After ED Visit for Overdose

Rose McNulty
There are significant racial disparities in outpatient referrals for opioid use disorder treatment, highlighting urgent need for targeted interventions in emergency care, according to a recent study.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo